[BIO] Bio-Rad Laboratories, Inc.

Overview

Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 183.48 Change: 0.83 (0.45%)
Ext. hours: Change: 0 (0%)

chart BIO

Refresh chart

Strongest Trends Summary For BIO

BIO is in the long-term up 161% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test sy

Fundamental Ratios
Shares Outstanding EPS2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -11.92% Sales Growth - Q/Q-20.96% P/E84.52
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.01% ROE4.55% ROI3.44%
Current Ratio4.08 Quick Ratio2.93 Long Term Debt/Equity0.34 Debt Ratio0.19
Gross Margin54.87% Operating Margin7.66% Net Profit Margin4.68% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-330 K Cash From Investing Activities-27.99 M Cash From Operating Activities29.45 M Gross Profit270.11 M
Net Profit17.82 M Operating Profit34.35 M Total Assets3.33 B Total Current Assets1.7 B
Total Current Liabilities416.88 M Total Debt435.93 M Total Liabilities1.13 B Total Revenue472.82 M
Technical Data
High 52 week317.41 Low 52 week233.97 Last close296.72 Last change-0.85%
RSI48.26 Average true range9.52 Beta0.73 Volume71.23 K
Simple moving average 20 days-0.93% Simple moving average 50 days-2.38% Simple moving average 200 days5.89%
Performance Data
Performance Week-4.62% Performance Month1.68% Performance Quart9.76% Performance Half2.09%
Performance Year10.07% Performance Year-to-date-3.49% Volatility daily1.85% Volatility weekly4.13%
Volatility monthly8.46% Volatility yearly29.32% Relative Volume236.57% Average Volume249.47 K
New High0.51% New Low

News

2020-02-25 16:15:00 | Bio-Rad to Present at Barclays Global Healthcare Conference 2020 on March 10

2020-02-24 17:47:34 | As coronavirus fears hit markets, why are these Bay Area stocks rising?

2020-02-14 10:35:36 | Cyberattack costs East Bay biotech company $20 million

2020-02-14 08:53:01 | Bio-Rad BIO Q4 Earnings & Revenues Fall Short of Estimates

2020-02-14 01:58:53 | Edited Transcript of BIO earnings conference call or presentation 13-Feb-20 10:00pm GMT

2020-02-13 18:45:11 | Bio-Rad Laboratories BIO Misses Q4 Earnings and Revenue Estimates

2020-02-13 18:23:00 | CORRECTING and REPLACING Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results

2020-02-06 12:30:05 | Bio-Rad Laboratories BIO Reports Next Week: Wall Street Expects Earnings Growth

2020-02-04 07:00:00 | Bio-Rad Brings FCS Express Flow Cytometry Analysis Software to ZE5 Cell Analyzer Users

2020-02-03 21:37:00 | Bio-Rad to Report Fourth-Quarter and Full-Year 2019 Financial Results Thursday, February 13, 2020

2020-01-09 05:40:52 | Is Bio-Rad Laboratories, Inc.'s NYSE:BIO ROE Of 7.3% Concerning?

2020-01-06 08:30:00 | Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President

2020-01-02 16:15:00 | Bio-Rad to Participate at the 38th Annual J.P. Morgan Healthcare Conference on January 13

2019-12-30 11:47:04 | Bio-Rad Gains on New Product Portfolio Despite Currency Woes

2019-12-25 14:35:10 | Bio-Rad Laboratories, Inc. BIO vs. Top 20 Hedge Fund Stocks in 2019

2019-12-23 08:30:00 | The International Trade Commission Issues Final Decision Affirming 10X Genomics Infringement of Three of Bio-Rad’s Patents

2019-12-13 16:52:00 | Bio-Rad Makes Progress Recovering from Recent Ransomware Attack

2019-12-11 05:23:04 | Why Bio-Rad Laboratories, Inc. NYSE:BIO Could Be Worth Watching

2019-11-30 14:28:15 | Hedge Funds Have Never Been This Bullish On Bio-Rad Laboratories, Inc. BIO

2019-11-26 12:11:05 | Bio-Rad's Blood Typing Market Growth Strong on New Products

2019-11-11 07:49:08 | Does Bio-Rad Laboratories NYSE:BIO Have A Healthy Balance Sheet?

2019-11-04 11:38:43 | Edited Transcript of BIO earnings conference call or presentation 31-Oct-19 9:00pm GMT

2019-11-01 12:03:04 | Bio-Rad Bio Q3 Earnings Beat Estimates on All-Line Growth

2019-10-31 16:15:00 | Bio-Rad Reports Third-Quarter 2019 Financial Results

2019-10-29 17:09:37 | This Hedge Fund Can Still Deliver Double Digit Returns: Here Are Its Top Picks

2019-10-24 10:32:02 | Bio-Rad Laboratories BIO Earnings Expected to Grow: Should You Buy?

2019-10-23 11:13:00 | 5 Companies Hit 52-Week Highs

2019-10-16 16:15:00 | Bio-Rad to Report Third-Quarter 2019 Financial Results Thursday, October 31, 2019

2019-10-15 12:05:58 | 5 Stocks to Buy in the Mighty Middle

2019-10-12 15:34:00 | Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. BIO

2019-10-08 10:36:02 | LabCorp LH Names Two Leaders for Major Business Wings

2019-10-07 06:36:10 | Bruker To Buy Freiberg Instruments' Magnettech EPR Business

2019-10-02 09:48:01 | Abbott ABT Gets FDA Nod for New Troponin-I Blood Test

2019-10-01 17:10:41 | It's not just Google: 'Fierce' competition for tech talent is pushing median salaries past $200K at many Silicon Valley companies

2019-09-18 09:07:09 | Goldman Sachs: 4 Conviction Buy Stocks To Snap Up Now

2019-09-12 17:28:48 | After record IPO, East Bay company's CEO targets growth — and sleep

2019-09-12 09:55:33 | On eve of biggest biotech IPO this year, 2 East Bay companies spar over patents

2019-09-11 17:48:00 | Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement

2019-08-31 09:31:01 | Bio-Rad BIO Up 8.8% Since Last Earnings Report: Can It Continue?

2019-08-29 18:13:45 | Biome Sees Revenue Quadruple, Gross Profits Triple In Q2

2019-08-29 15:20:07 | Edited Transcript of BIO earnings conference call or presentation 1-Aug-19 9:00pm GMT

2019-08-23 06:51:10 | Here's Why You Should Retain Bio-Rad BIO Stock for Now

2019-08-21 18:56:00 | Fitch Ratings Upgrades Bio-Rad to BBB, ‘Outlook Stable,’ Reflecting Continued Improvement in the Company’s Operating Performance

2019-08-19 17:45:47 | How a biotech revolution catapulted this East Bay company to a $100M IPO

2019-08-13 07:00:00 | The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook

2019-08-09 09:30:01 | PRGO vs. BIO: Which Stock Is the Better Value Option?

2019-08-02 09:15:01 | Bio-Rad Bio Q2 Earnings Beat Estimates, Margins Expand

2019-08-01 20:26:34 | Bio-Rad Laboratories Inc BIO BIO-B Q2 2019 Earnings Call Transcript

2019-08-01 18:15:10 | Bio-Rad Laboratories BIO Surpasses Q2 Earnings and Revenue Estimates

2019-08-01 16:15:00 | Bio-Rad Reports Second-Quarter 2019 Financial Results